The Russian retail market for therapeutic enteral nutrition (including online channels) has shown double-digit growth for the second year in a row. In Q1-Q2 2025, sales in rubles grew by 19.3%, while consumption increased by 14.3% compared to the same period in 2024. According to information from the database “Audit of retail sales of specialized nutrition in Russia (total sell out)” by the analytical company RNC Pharma, from January to June of this year, 8.1 million packages (more than 2,000 tons) of the analyzed products were sold for a total of 3.4 billion rubles (at retail prices, including VAT). In total, 14.8 million packages (3,700 tons) were sold at retail in 2024, amounting to 6 billion rubles.

In this category, the rapid development of the e-commerce segment continues. Compared to Q1-Q2 2024, online sales of enteral nutrition increased by 36.3% in value terms. Demand also grew in traditional outlets, but the growth rate was significantly lower, at 11.4%. During the period under review, the online share increased by 3.5 percentage points (p.p.) to 35.9% in rubles. The consumption of therapeutic nutrition in the e-commerce segment grew by 29.2% over the year, while offline growth was 9.3%, with the share of online sales reaching 28.5% during this period.

At the end of the first half of 2025, there were 44 therapeutic nutrition brands on the market, comprising 316 SKUs. During this period, 16 companies represented their products in retail, with over 84% of consumer spending in the category accounted for by products from the top three brands. For several years, the Dutch company Nutricia (a division of Danone) has been the absolute leader in the market, accounting for more than 36.9% of the market's ruble volume. In this category, the corporation had 10 brands during the reporting period, the key one being Nutridrink, which accounts for about 85% of the company's natural sales volume. In second place is the American company Abbott, which accounts for 32.2% in rubles. It is important to note that in real terms, Abbott is the undisputed leader (62% in packages), while Nutricia controlled only 16.5% of sales. The French company Nestlé rounds out the top three with a 15.3% share in rubles and 5.9% in packages. The sales dynamics of these companies differ significantly, with Nutricia adding 19% over the year, which actually corresponds to the average growth rate for the industry. Abbott's performance is slightly more modest, at around 16%, while Nestlé is the worst performer among the leaders, with sales growing by only 9% over the year.

Half of the top ten are Russian manufacturers, but their share of the total volume is still small: only about 12% in volume terms and 9% in value terms. The overall ruble dynamics for domestic manufacturers' products is recorded at 61% in rubles. The largest sales volume among domestic players is recorded by Infaprim, which occupies 5.8% of the market in rubles. The company represents two products on the retail market: Nutrien and Nutrigen. All TOP-10 participants showed steady growth in the first half of the year, with the highest figures recorded by Pharmalact, whose sales increased 6.7 times in rubles and 9.4 times in packages over the year. At the end of last year, a new specialized product for dietary therapeutic nutrition for patients with phenylketonuria from Art Sovremennye Nauchnye Tekhnologii also entered the market, and the manufacturer immediately entered the top ten leaders.

Among all brands presented on the retail market in the first half of 2025, Pediasure, manufactured by Abbott, retains its leading position with a 16.3% increase in sales in rubles. Nutridrink from Nutricia retains its second position, with sales growing by 22.2% over the year. The top three is rounded out by Alfar from Nestlé. Compared to January-June 2024, there was a 3.1% decline in the brand's natural consumption, but ruble dynamics were recorded at 6.1%.

Table. Top 10 corporations in the Russian retail market for therapeutic enteral nutrition, by cash sales volume in Q1–Q2 2025